Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 40 clinical trials
Clinical Study of Combination Therapy With Ectiecinib Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.

This single-arm, open, multicenter clinical study is going to evaluate the efficacy and safety of combination therapy with ectiecinib, pemetrexed and platinum in patients with metastatic non-squamous non-small cell lung cancer with EGFR mutations who did not progress after pemetrexed in combination with platinum-based chemotherapy.

inulin clearance
measurable disease
squamous non-small cell lung carcinoma
pemetrexed
lung cancer
  • 0 views
  • 23 Jan, 2021
  • 1 location
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Lung cancer remains the most lethal malignancy in both sexes around the world. It is estimated that lung cancer caused 234,030 deaths in the United States in 2016, accounting for 28% of all cancer-related deaths. In 2012 alone, a total of 6,697 deaths from lung cancer were registered in Mexico; …

  • 0 views
  • 18 Feb, 2021
  • 1 location
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC Retrospective Study

This is a nationwide, multicenter and retrospective cohort study. The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer.

EGFR
lung carcinoma
  • 0 views
  • 30 Jul, 2021
  • 18 locations
Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib

Recently it has been suggested that specific mutations in the EGFR gene in lung cancer patients is associated with response to a novel drug targeting the EGF system. Recent research also indicates that there is a possible association to the degree of aggressiveness of the disease. The importance of these …

EGFR
epidermal growth factor receptor
growth factor
erlotinib
carcinoma
  • 6 views
  • 07 Nov, 2020
  • 1 location
A Retrospective Pharmacogenomics Research of EGFR-TKIs Gefitinib and Erlotinib in NSCLC Patients Treatment

detection and gefitinib and erlotinib administration based on EGFR-TKIs sensitive mutations.From clinical points of view ,individual differences often occur between different patients, leading diverse

EGFR
gefitinib
erlotinib
crizotinib
lung carcinoma
  • 4 views
  • 26 Jan, 2021
  • 1 location
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care

like erlotinib and vemurafenib. However, tumor genotyping can be slow and cumbersome, and is limited by availability of tumor biopsy tissue for testing. The aim of this study is to prospectively

braf v600e mutation
lung cancer
vemurafenib
BRAF
NRAS
  • 10 views
  • 26 Sep, 2021
  • 1 location
Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

This study aims to explore the efficacy and safety of Erlotinib/Gefitinib combined with bevacizumab in the real world for advanced non-squamous cell lung cancer with EGFR mutation, explore new

bevacizumab
EGFR
gefitinib
erlotinib
lung carcinoma
  • 6 views
  • 24 Jan, 2021
  • 1 location
Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV)

The study will explore the characteristics in clinical pharmacokinetics of gefitinib, erlotinib,afatinib,osimertinib, crizotinib, apatinib, icotinib in Chinese patients of Non-small-cell lung

epidermal growth factor receptor
hepatitis
epidermal growth factor
afatinib
tyrosine
  • 5 views
  • 22 Jan, 2021
  • 1 location
Osimertinib for Advanced EGFR-positive NSCLC Patients

EGFR-TKIs gefitinib and erlotinib bind competitively to the ATP-binding site of EGFR TK domain. This binding in second-generation TKI afatinib is irreversible. These drugs have improved better outcome

cancer chemotherapy
afatinib
tyrosine
EGFR
osimertinib
  • 0 views
  • 16 Sep, 2021
  • 1 location
Study on Bisphosphonates Targeting Triple-negative Breast Cancer

can be chimeric with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, which can synergistically inhibit the in vitro tumor formation of cancer (such as non-small-cell lung

estrogen receptor
progesterone receptor
estrogen
bisphosphonate
mammogram
  • 0 views
  • 30 Jul, 2021
  • 3 locations